Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma

FRIDAY, Sept. 1, 2023 -- For patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma, zolbetuximab, a monoclonal antibody that...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news